Document is current
Any future updates will be listed below
-
Authors
Cheng, Caleb https://orcid.org/0000-0003-1872-2661
Hu, Jing https://orcid.org/0000-0001-7604-6732
Mannan, Rahul https://orcid.org/0000-0002-6642-0468
He, Tongchen
Bhattacharyya, Rupam https://orcid.org/0000-0003-4292-2372
Magnuson, Brian
Wisniewski, Jasmine P. https://orcid.org/0009-0005-1481-6478
Peters, Sydney
Karim, Saadia A. https://orcid.org/0000-0002-3727-0667
MacLean, David J. https://orcid.org/0000-0003-4932-2839
Karabürk, Hüseyin https://orcid.org/0000-0002-3458-9445
Zhang, Li
Rossiter, Nicholas J. https://orcid.org/0000-0001-7333-1546
Zheng, Yang https://orcid.org/0000-0002-6793-3206
Xiao, Lanbo
Li, Chungen
Awad, Dominik https://orcid.org/0000-0002-7386-2061
Mahapatra, Somnath
Bao, Yi
Zhang, Yuping https://orcid.org/0000-0002-8727-5183
Cao, Xuhong
Wang, Zhen https://orcid.org/0000-0001-8762-6089
Mehra, Rohit https://orcid.org/0000-0002-6955-8884
Morlacchi, Pietro
Sahai, Vaibhav https://orcid.org/0000-0003-1892-1548
Pasca di Magliano, Marina
Shah, Yatrik M. https://orcid.org/0000-0002-2487-4816
Weisman, Lois S. https://orcid.org/0000-0001-7740-9785
Morton, Jennifer P. https://orcid.org/0000-0001-5766-9141
Ding, Ke
Qiao, Yuanyuan https://orcid.org/0000-0002-1178-3480
Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
Chinnaiyan, Arul M. https://orcid.org/0000-0001-9282-3415
- License Information
-
More Information
Article History
Received: 12 March 2024
Accepted: 19 March 2025
First Online: 23 April 2025
Competing interests
: A.M.C. is a co-founder and serves on the scientific advisory board of Esanik Therapeutics, which owns proprietary rights to the clinical development of ESK981. Esanik Therapeutics did not fund or approve the conducting of this study. A.M.C. is a co-founder and serves on the scientific advisory board of Medsyn Bio, Lynx Dx and Flamingo Therapeutics. A.M.C. serves as an advisor to Tempus, Proteovant, Aurigene Oncology, RAPTTA Therapeutics and Ascentage Pharmaceuticals. A.M.C., Y.Q., C.A.L., C.C., Y.B., K.D., Z.W. and C.L. are listed as inventors on the following patents pertaining to the development of methodologies and compounds targeting PIKfyve in diseases: PCT: PCT/US2021/057022 (A.M.C. and Y.Q.); PCT: PCT/US2024/017088 (A.M.C. and Y.Q.); PCT: PCT/CN2024/087809 (A.M.C., Y.Q., Z.W., K.D. and C.L.), US patent no: 63/537,996 (A.M.C., Y.Q. and Y.B.), US patent no: PCT/CN2024/078381 (C.A.L., A.M.C., K.D., Y.Q., Z.W. C.L., and C.C.). In the past three years, C.A.L. has consulted for Astellas Pharmaceuticals, Odyssey Therapeutics, Third Rock Ventures and T-Knife Therapeutics, and he is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer and targeting the GOT1-ME1 pathway as a therapeutic approach (US patent no. 2015126580-A1, 2015; US patent no. 20190136238, 2019; and international patent no. WO2013177426-A2, 2015). The remaining authors declare no competing interests.
